Last reviewed · How we verify
GW815SF HFA MDI
GW815SF is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via pressurized metered-dose inhaler for maintenance treatment of asthma and COPD.
GW815SF is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via pressurized metered-dose inhaler for maintenance treatment of asthma and COPD. Used for Maintenance treatment of asthma, Maintenance treatment of COPD.
At a glance
| Generic name | GW815SF HFA MDI |
|---|---|
| Also known as | salmeterol/fluticasone propionate combination |
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
The drug combines fluticasone propionate (ICS) to reduce airway inflammation and beclomethasone or similar LABA component to provide bronchodilation and symptom relief. The HFA (hydrofluoroalkane) propellant formulation enables efficient delivery to the lungs via MDI, providing dual anti-inflammatory and bronchodilatory effects for chronic obstructive airway diseases.
Approved indications
- Maintenance treatment of asthma
- Maintenance treatment of COPD
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Throat irritation
Key clinical trials
- Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study- (PHASE3)
- Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW815SF HFA MDI CI brief — competitive landscape report
- GW815SF HFA MDI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI